BRIEF-EMA Approves Comirnaty COVID-19 Vaccine For Children Aged 5 To 11

* EMA SAYS IN CHILDREN FROM 5 TO 11 YEARS OF AGE, DOSE OF COMIRNATY WILL BE LOWER THAN THAT USED IN PEOPLE AGED 12 AND ABOVE (10 ΜG COMPARED WITH 30 ΜG). * EMA: AS IN THE OLDER AGE GROUP, IT IS GIVEN AS TWO INJECTIONS IN THE MUSCLES OF THE UPPER ARM, THREE WEEKS APART.

European Medicines Agency: * EMA ON PFIZER COVID-19 VACCINE: COMIRNATY COVID-19 VACCINE: EMA RECOMMENDS APPROVAL FOR CHILDREN AGED 5 TO 11

* EMA SAYS THE VACCINE, DEVELOPED BY BIOTECH AND PFIZER, IS ALREADY APPROVED FOR USE IN ADULTS AND CHILDREN AGED 12 AND ABOVE. * EMA SAYS IN CHILDREN FROM 5 TO 11 YEARS OF AGE, DOSE OF COMIRNATY WILL BE LOWER THAN THAT USED IN PEOPLE AGED 12 AND ABOVE (10 ΜG COMPARED WITH 30 ΜG).

* EMA: AS IN THE OLDER AGE GROUP, IT IS GIVEN AS TWO INJECTIONS IN THE MUSCLES OF THE UPPER ARM, THREE WEEKS APART. * EMA: CONCLUDED BENEFITS OF COMIRNATY IN CHILDREN AGED 5 TO 11 OUTWEIGH RISKS, PARTICULARLY IN THOSE WITH CONDITIONS THAT INCREASE RISK OF SEVERE COVID-19

* EMA SAYS THE CHMP WILL NOW SEND ITS RECOMMENDATION TO THE EUROPEAN COMMISSION, WHICH WILL ISSUE A FINAL DECISION. Further company coverage:

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)